Grant to Novartis Sample Clauses

Grant to Novartis. (a) Subject to the other provisions of this Agreement, VERTEX hereby grants to NOVARTIS an exclusive worldwide license under VERTEX Technology to the extent useful to permit NOVARTIS to carry out its rights and obligations set forth in this Agreement and to develop, manufacture, have manufactured, market, use, sell and import for sale, as provided herein, Bulk Drug Substance, Drug Product Candidates and Drug Products worldwide. NOVARTIS shall have the right to sublicense under this Agreement. Subject to the provisions of this Agreement, VERTEX shall have the right to use VERTEX Technology to discharge its obligations and exercise its rights under this Agreement. VERTEX retains all rights to VERTEX Technology except to the extent explicitly granted to NOVARTIS hereunder.
Sample 1Sample 2
AutoNDA by SimpleDocs
Grant to Novartis. Amgen hereby grants to Novartis, effective as of the Effective Date (without any further action by either Party), [*], royalty-free right and license during the Term, subject to the terms and conditions hereof, solely to conduct Medical Affairs Activities with respect to and Commercialize the Product in the Field in the United States under Amgen Product Trademarks designated by Amgen for use with the Product in accordance with the Commercialization Plan and this Agreement. Amgen hereby grants to Novartis [*], royalty-free license to use the Amgen Housemarks solely as set forth in the Promotional Materials, Non-Promotional Materials and other materials provided to it by Amgen, and solely to sell, import, conduct Medical Affairs Activities with respect to and otherwise Commercialize the Product in the Field in the United States in accordance with the Commercialization Plan and this Agreement. Such licenses shall include the right to sublicense only as set forth in Section 3.3 (Sublicensing). 3.5.3
Sample 1
Grant to Novartis. (a) Subject to the terms and conditions of this Development License and Commercialization Agreement and the Manufacturing and Supply Agreement, Cell Genesys hereby grants to Novartis an exclusive right and license in the Option Territory under the Cell Genesys Technology to develop, manufacture, have manufactured, export, import, market, use, offer to sell, sell and register, and otherwise exploit, the Option Product in the Field. Novartis shall have the right to grant sublicenses freely to any Third Party of its choosing under this Development License and Commercialization Agreement. For the avoidance of any doubt, "exclusive" under this Section 2.1 (a) shall mean that neither Cell Genesys nor any other Third Party shall have any rights under the Cell Genesys Technology with respect to the Option Product; provided, however, subject to the terms and conditions of this Development License and Commercialization Agreement, Cell Genesys shall have the right to use Cell Genesys Technology to comply with its obligations and exercise its rights under this Development License and Commercialization Agreement and the Manufacturing and Supply Agreement.
Sample 1
Grant to Novartis. Amgen hereby grants to Novartis, effective as of the Effective Date, with respect to Franchise Product 1 and Franchise Product 2, and effective as of the Option Exercise Date, with respect to Franchise Product 3 (without any further action by either Party), [*] (except as otherwise expressly set forth herein (such exception to include the transition period described in Section 15.5 (Transition Period))) right and license during the Term, subject to the terms and conditions hereof, solely to research, Develop, conduct Medical Affairs Activities with respect to, use, sell, import and otherwise Commercialize the applicable Licensed Product in the Field in the Territory under the same Licensed Amgen Trademarks as used by Amgen, its Affiliates or permitted licensees or sublicensees for such Licensed Amgen Ref. No. 2015641252 Page 26 Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been filed with the Securities and Exchange Commission. Product in the corresponding indications outside the Territory. In the event that Amgen has identified a Licensed Amgen Trademark to be so used, and is developing plans to so use such Licensed Amgen Trademark, the foregoing license shall permit Novartis to similarly conduct such planning activities in the Territory to the same extent of Amgen’s planning activities outside the Territory. Each Party shall provide regular updates to the other Party regarding proposed Licensed Amgen Trademarks and Licensed Novartis Trademarks, as the case may be. Such license shall include the right to sublicense only as set forth in Section 4.3 (Sublicensing). Should Novartis desire that a different trademark be used for a given Licensed Product in the Field in the Territory, or if additional trademarks to those used outside the Territory are otherwise required, Novartis shall be entitled to do so after consulting with Amgen and giving due consideration to Amgen’s reasonable comments regarding an additional or replacement trademark (or trademarks). Such replacement or additional trademark(s) shall be registered and owned by Novartis in the Territory. At Amgen’s election and with the approval of the applicable Governmental Authority, the labeling, packaging and materials for any Licensed Product supplied by or on behalf of Amgen to Novartis hereunder shall include Amgen Housemarks in equal prominence with Novartis Housemarks, provided that Amgen shall inform Novartis...
Sample 1
Grant to Novartis. 10 2.2 Grant to VERTEX.......................................................................................11 2.3 Information Transfer..................................................................................11
Sample 1
Grant to Novartis. License, Development and Commercialization Agreement -- Confidential -- Page 6
Sample 1
Grant to Novartis. Amgen hereby grants to Novartis, effective as of the Restated Effective Date (without any further action by either Party), [***], royalty-free right and license during the Transition Period, subject to the terms and conditions hereof, solely to conduct Medical Affairs Activities with respect to and Commercialize the Product in the Field in the United States under Amgen Product Trademarks designated by Amgen for use with the Product solely in connection with the Transitional Medical Affairs Activities and Transitional Commercialization Activities or otherwise as needed in connection with activities under the Transition Services Agreement. Amgen hereby grants to Novartis [***], royalty-free license during the Transition Period to use the Amgen Housemarks solely as set forth in the Promotional Materials, Non-Promotional Materials and other materials provided to it by Amgen, and solely to sell, import, conduct Medical Affairs Activities with respect to and otherwise Commercialize the Product in the Field in the United States solely in connection with the Transitional Medical Affairs Activities and Transitional Commercialization Activities or otherwise as needed in connection with activities under the Transition Services Agreement. Such licenses shall include the right to sublicense only as set forth in Section 3.3 (Sublicensing).
Sample 1
AutoNDA by SimpleDocs
Grant to Novartis. In the event that (i) Midatech terminates this agreement pursuant to Section 9.2.2 or (ii) Novartis terminates this Agreement pursuant to Section 9.2.1, Midatech shall, and hereby does, grant to Novartis a [***], fully paid-up and royalty-free, perpetual, irrevocable, right and license in the Territory, for any and all uses and purposes, with the right to freely assign and grant sublicenses solely to Novartis’ Affiliates, under Midatech’s rights in the Midatech Information and Improvements (including the Midatech Safety Data).
Sample 1

Related to Grant to Novartis

  • Exclusive License Grant Subject to the terms and conditions of this Agreement (including Section 3.5.1 (Takeda Retained Rights)), Takeda hereby grants to Licensee an exclusive, sublicensable (subject to Section 3.3 (Sublicensing)), royalty-bearing right and license under the Takeda Technology and Takeda’s interest in the Joint Technology to Exploit the Licensed Compounds and Licensed Products in the Field in the Licensee Territory.

  • License Grant If Products include software, firmware or documentation, Supplier grants to DXC a non-exclusive, perpetual, royalty free, worldwide license to use, reproduce, display, prepare derivative works of the documentation and distribute such works, software, firmware or documentation directly or as integrated into DXC products, and to sublicense such rights to third parties. Supplier shall identify all licenses and deliver to DXC all materials required to meet the requirements of any licenses for third party software that is included in the Products. Supplier shall deliver to DXC the source code for any software licensed under a license that has a source availability requirement (such as the GNU General Public License). If the source code is not included with the material that Supplier has previously delivered, Supplier shall deliver within seven (7) days after DXC’s request the source code for any software licensed under an open source license that has a source availability requirement. Supplier grants DXC the right to duplicate and distribute the materials as necessary.

  • Sublicense Grant Licensee will be entitled to grant Sublicenses to third parties under the license granted pursuant to Section 2.1 subject to the terms of this Section 2.3. Any such Sublicense shall be on terms and conditions in compliance with and not inconsistent with the terms of this Agreement. The grant of a Sublicense shall not in any way diminish or alter Licensee’s obligations under this Agreement.

  • Grant of Stock Option The Company grants to Employee the right and option (hereinafter referred to as the "Option") to purchase all or any part of up to ________ shares of the Company's Common Stock (the "Option Shares") on the terms and conditions set forth below and in the Plan.

  • Stock Option Agreement Each grant of an Option under the Plan shall be evidenced by a Stock Option Agreement between the Optionee and the Company. Such Option shall be subject to all applicable terms of the Plan and may be subject to any other terms that are not inconsistent with the Plan. The Stock Option Agreement shall specify whether the Option is an ISO or an NSO. The provisions of the various Stock Option Agreements entered into under the Plan need not be identical. Options may be granted in consideration of a reduction in the Optionee’s other compensation.

  • Stock Option Grant Subject to the provisions set forth herein and the terms and conditions of the Plan, and in consideration of the agreements of the Participant herein provided, the Company hereby grants to the Participant an Option to purchase from the Company the number of shares of Common Stock, at the exercise price per share, and on the schedule, set forth above.

  • Option Grant You have been granted a Non-Statutory Stock Option (referred to in this Agreement as your “Option”). Your Option is not intended to qualify as an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended.

  • Grant of Sublicense Subject to the terms and conditions of this Agreement, Adviser hereby grants to the Trust a non-transferable sublicense to use the Index (and associated data and information) listed on Exhibit A in the manner set forth in, and subject to the terms of, the License Agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.